CX-4945 (Silmitasertib)

Catalog No.S2248

CX-4945 (Silmitasertib) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Phase 1/2.

Price Stock Quantity  
USD 291 In stock
USD 170 In stock
USD 320 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

CX-4945 (Silmitasertib) Chemical Structure

CX-4945 (Silmitasertib) Chemical Structure
Molecular Weight: 349.77

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Casein Kinase Inhibitors
    Compare Casein Kinase Products
  • Inhibition Profile
  • CX-4945 (Silmitasertib) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description CX-4945 (Silmitasertib) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Phase 1/2.
Targets CK2 [1]
(Cell-free assay)
IC50 1 nM
In vitro CX-4945 is selective for CK2, as it only inhibits 7 of the 238 kinases by more than 90% at concentration of 0.5 μM, which is 500-fold greater than the IC50 of CK2. Although in cell-free systems CX-4945 inhibits FLT3, PIM1, and CDK1 with IC50 of 35 nM, 46 nM, and 56 nM, respectively, CX-4945 treatment at 10 μM is inactive against FLT3, PIM1, and CDK1 in cell-based functional assays. CX-4945 exhibits a broad spectrum of antiproliferative activity, and the breast cancer cell lines displays the widest range of sensitivity to CX-4945 with EC50 of 1.71-20.01 μM. The antiproliferative activity of CX-4945 correlates with CK2α mRNA and protein levels but not the CK2α' catalytic subunit, the regulatory CK2β subunit, and the PI3K/Akt or PTEN mutational status. CX-4945 inhibits PI3K/Akt signaling by directly blocking the phosphorylation of Akt at Serine 129 by CK2 rather than through activation of PTEN. CX-4945 treatment causes reduced phosphorylation of p21 (T145), increased levels of total p21 and p27, and induction of caspase 3/7 activity. CX-4945 treatment induces a G2/M cell-cycle arrest in BT-474 cells and a G1 arrest in BxPC-3 cells. CX-4945 inhibits HUVEC proliferation, migration, and tube formation with IC50 of 5.5 μM, 2 μM, and 4 μM, respectively. Under hypoxic conditions in BT-474 and BxPC-3 cells, CX-4945 treatment prevents downregulation of p53 and pVHL and reduces activation of HIF-1α transcription. [1] CX-4945 potently inhibits endogenous intracellular CK2 activity with IC50 of 0.1 μM in Jurkat cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
plateletsNETzcVhMcW6jc3WgRZN{[Xl?MlixNU82NzFyIN88US=>NGPLWHExNjViaB?=M3\YeGROW09?Mo\KdoVlfWOnczDDT|Ihc2mwYYPlJIFkfGm4aYT5JIFv\CCybHH0[YxmfCCjZ3fy[YdifGmxbh?=M1G3XFI3OzhzNEO3
HDMECNG[3RppMcW6jc3WgRZN{[Xl?NVOxNIFMOC5{NT:wMlUwOSEQvF2=NE\YOZYzPCCqNXewTYpzTE2VTx?=MnPIdoVlfWOnczDDT|Ihc2mwYYPlJIFkfGm4aYT5MEB3X0ZiZYjwdoV{e2mxbjDhcoQhe2WlcnX0bY9vNWTvU2JLOjZ|OEG0N|c>
HDMECMYnGeY5kfGmxbjDBd5NigQ>?NHy0c2QxNjJ3L{CuOU8yKM7:TR?=MUWyOEBpNFnqOHFFVVORMlXudoVlfWOnczDlfJBz\XO|aX;uJI9nKF[FQV2tNUBjfXRibn;0JGlESU1vMR?=M2\XR|I3OzhzNEO3
HDMECM1XPOmZ2dmO2aX;uJGF{e2G7NHTyXooyKM7:TR?=NGr4[IkzPCCqM2jLcmROW09?MXjh[oZm[3S|IIP1ZoNmdGy3bHHyJIxw[2GuaYrheIlwdiCxZjDOSmFV[zFiYX7kJJBpd3OyaH:tdFY2MXuyOlM5OTR|Nx?=
A549 M3jNXmZ2dmO2aX;uJGF{e2G7NHXoW|g{NzFywrFOwG0>M{S5d|Q5KGh?M1jqd5N2eHC{ZYPz[ZMhfGinIH3pZ5JweGmubHHyMYlv\HWlZXSg[ZhxemW|c3nvckBw\iCyLV\BTy=>NXy2OpA2OjZ|MUi4NFA>
HDMECNEfnTYxMcW6jc3WgRZN{[Xl?MlTmNU02OCEQvF2=NHLmO|M2KGh?Mk\BSG1UVw>?MYrk[YNz\WG|ZYOgR2szKGurbnHz[UBi[3Srdnn0fUB4cXSqb4X0JIFn\mWldHnu[{Bk\WyuII\pZYJqdGm2eR?=NHfsVmMzPjF6OUW4Oi=>
HDMECNV\KXIZ4TnWwY4Tpc44hSXO|YYm=NUi4eZRmPTBizszNMnH4NU82KGh?MVvEUXNQMknn[IVkemWjc3XzJJRp\SCwdXPs[YFzKHOrZ37hcEBw\iCyaH;zdIhwenmuYYTl[EBxPjViaX6gWG5HNc7zLYP0bY12dGG2ZXSgTGROTUQEoB?=NVjoe4cyOjZzOEm1PFY>
HEK293MWLLbY5ie2ViQYPzZZk>MWGwMlXDqM7:TR?=NXn0NoRSOTVibXnuM16wfGROW09?MXzy[YR2[2W|IFPLNkBscW6jc3WgZYN1cX[rdIm=NY\RZYJKOjV6OEe2NlY>
HelaNH3LenlMcW6jc3WgRZN{[Xl?M3PVPVAvPcLizszNM4DOUlE2KG2rbh?=NIXkNoxFVVORNYC3dFVDemWmdXPld{BEUzJia3nuZZNmKGGldHn2bZR6MkHXNlU5QDd4Mk[=
LAMA84NI\4bnlMcW6jc3WgRZN{[Xl?M{O5SlAvPcLizszNMXqxOUBucW5?M3XwRmROW09?M2LhU5Jm\HWlZYOgR2szKGurbnHz[UBi[3Srdnn0fS=>NESze3AzPTh6N{[yOi=>
HEK293MX3GeY5kfGmxbjDBd5NigQ>?MV:zJO69VQ>?NXLkNWw3PSCqMV;EUXNQNEPxOHdEUzJicHjvd5Bpd3K7bHH0[ZMh\UmIM3qgZZQhW2W{MUK3NYD0ZYlSOjV6OEe2NlY>
UM-SCC1MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV6wMlEuOzBizszNNGnwW3AyNTViZB?=MYPJR|UxRTRwMTFOwG0>M4fOUFI2Pzl6ME[x
UM-SCC46NWHJblAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoraNE4yNTNyIN88US=>NHfyXVMyNTViZB?=MXnJR|UxRTNwNDFOwG0>MWWyOVc6QDB4MR?=
UM-SCC1MljDSpVv[3Srb36gRZN{[Xl?NUHtVIRMOC53L{SvNVAh|ryPNVPaeo5LPzJiaB?=NXTje2h7\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gUmYuzLiELDDCZ4wuYExiYX7kJJVxNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCyNUOsJJAzOSxiQWCtNUBidmRiSVytPEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5NEPWN5UzPTd7OEC2NS=>
UM-SCC46M3XC[mZ2dmO2aX;uJGF{e2G7MWmwMlUwPC9zMDFOwG0>Mn:zO|IhcA>?NFj0eVNld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDOSk3FwEJuIFLjcE1ZVCxicEWzMEBxOjFuIFHQMVEh[W6mIIXwMZJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDJUE05KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>M1y5[FI2Pzl6ME[x
NU-DULMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUe1MVI2KM7:TR?=MkX0OFghcA>?MVfpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5MYSyOVc5QDJ4OR?=
Oci Ly 3MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;1OU0zPSEQvF2=NYnpUlR7PDhiaB?=Mom0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>MnHqNlU4QDh{Nkm=
Oci Ly 10Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzQOU0zPSEQvF2=NVTGfFdEPDhiaB?=MkTtbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>NXqwWmNIOjV5OEiyOlk>
Oci Ly 1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\JUVUuOjVizszNNETw[VU1QCCqMl;YbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>Mk\KNlU4QDh{Nkm=
Oci Ly 18MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jtWVUuOjVizszNM164V|Q5KGh?NWTZOFJbcW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>?NX36R4pROjV5OEiyOlk>
Oci Ly 19 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj6NGx3PS1{NTFOwG0>NEj1fnk1QCCqM1TMZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>M3\2R|I2Pzh6Mk[5
RajiNYTWTWh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXW1MVI2KM7:TR?=MknaOFghcA>?Mn3ibY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>NGjw[XczPTd6OEK2PS=>
H1299MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzZXIQyNzVxMUCg{txOM3zP[FczKGh?MmXjbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>NWnwb252OjV5NUCzNFg>
Calu-1 NI\SeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzONXcyNzVxMUCg{txONHvNOWk4OiCqM{HuWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>MX6yOVc2ODNyOB?=
H358Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFL4VZUyNzVxMUCg{txOM2rm[|czKGh?NVnSZYV{cW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>?MXOyOVc2ODNyOB?=
H1299Ml\URZBweHSxc3nzJGF{e2G7MkL3NVAh|ryPMXe3NkBpNFjGRlBqdmS3Y3XzJIFxd3C2b4Ppdy=>NXzu[pBvOjV5NUCzNFg>
Calu-1 M1rrbmFxd3C2b4Ppd{BCe3OjeR?=MVOxNEDPxE1?NH;SZnc4OiCqNVvmfmNQcW6mdXPld{BieG:ydH;zbZM>M1jRc|I2PzVyM{C4
H358NIXUV3ZCeG:ydH;zbZMhSXO|YYm=Mn;3NVAh|ryPMVu3NkBpNGLJdpRqdmS3Y3XzJIFxd3C2b4Ppdy=>MlTONlU4PTB|MEi=
PC9/GRMnf2SpVv[3Srb36gRZN{[Xl?NYTEPXA1PSEEtV2=MlzqOFghcA>?MlzxbY5lfWOnczDheZRweGijZ4m=NITiWHIzPTR6NkSwPS=>
PC9/ERMojiSpVv[3Srb36gRZN{[Xl?NYTFTpVNPSEEtV2=NVn5S|YyPDhiaB?=NUfrUYVCcW6mdXPld{BifXSxcHjh[5k>M1O3clI2PDh4NEC5
H28M1;E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTFNE4xOS1|MDFOwG0>NX;l[npoPzJiaB?=MUDEUXNQM4rERmlEPTB;Nz6yJO69VQ>?M176Z|I2PDJ{MEix
H2052MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETmenQxNjBzLUOwJO69VQ>?NVXs[JRCPzJiaB?=NYf6XGZCTE2VTx?=MnX4TWM2OD1{LkCg{txOMoLvNlU1OjJyOEG=
UM-SCC-1MlXkR4xwdm:pZX7pZ{BCe3OjeR?=M2TW[lAvPS13IN88US=>MUixOEBlMUHEUXNQM1jMWOKhcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCjbnSgd5Bp\XKnIH\vdo1ifGmxbh?=NGPHT5gzPTN5OUCxOi=>
UM-SCC-46NHTnNXREdG:wb3flcolkKEG|c3H5M4rY[FAvPS13IN88US=>NWrmRpF5OTRiZB?=NE\IT3BFVVORM332NOKhcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCjbnSgd5Bp\XKnIH\vdo1ifGmxbh?=Mlf4NlU{PzlyMU[=
U87-MGMoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn36NU82NzFyIN88US=>NFTYeXozPC92OD:3NkBpMV7EUXNQMmm3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh[m:2aDDjc45k\W62cnH0bY9vKGGwZDD0bY1mKGSncHXu[IVvfGy7MWiyOVI1OTh7Nx?=
MDA-MB-231MV;GeY5kfGmxbjDBd5NigQ>?M3;De|IwPS9zMDFOwG0>M{HhUFQhcA>?NIn4U|hl\WO{ZXHz[ZMhfGinIHPvcpN1cXS3dHn2[UBxcG:|cHjvdplt[XSrb36gc4Yh[m:2aDCgdE1UPTJ7LYC2OUBidmRicD3TNVI6NUGtdB?=NEXFTIIzPTF3M{eyOS=>
MDA-MB-231MnjqSpVv[3Srb36gRZN{[Xl?M2OzelIwPS9zMDFOwG0>NVn4Z2tXPCCqNInVblBqdmirYnn0d{B{\XKrbnWgOVI6KHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIV5eHKnc4Ppc44hd2ZiSVytOkwhUUxvOB?=NF;tWmEzPTF3M{eyOS=>
ARPE-19MWjLbY5ie2ViQYPzZZk>MU[1M|ExNzJyIN88US=>NEXubJUzPC92ODDoNV3iSXBscW6qaXLpeJMhS0t{IHvpcoF{\SCjY4Tpeol1gSCjdDDhJINwdmOnboTyZZRqd25ib3[gOeKh|ryPNWPOXFk1OjR4OE[wPFA>
ARPE-19M2jy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWGxNEDPxE1?NHnhNIQzPC17NjDoMlzOSG1UVw>?NV7nZVFUcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>?M4HMS|I1Pjh4MEiw
HCT116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG1NVAh|ryPMW[yOE06PiCqM1uzU2ROW09?MnrnbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>NIOyO4IzPDZ6NkC4NC=>
ARPE-19M{PidWZ2dmO2aX;uJGF{e2G7M1XoSVExKM7:TR?=MkLzOEBpMYXEUXNQMUPjZZV{\XNiRWKtd5Rz\XO|IILld5BwdnOnIH;2[ZIhfGinIICt[WlHOs7zIHLyZY5kcCxiYoX0JIRw\XNibn;0JIlv\HWlZTDDTG9RyqB?MnzqNlQ3QDZyOEC=
HCT116 MV;GeY5kfGmxbjDBd5NigQ>?MlPGNVAh|ryPMmrqOEBpNGPoR2xFVVORM{P6[INifXOnczDFVk1{fHKnc4OgdoV{eG:wc3Wgc5ZmeiC2aHWgdE1mUUZ{zsGgZpJidmOqLDDieZQh\G:nczDuc5QhcW6mdXPlJGNJV1EEoB?=NEDNO2kzPDZ6NkC4NC=>
HCT116 MVzBdI9xfG:|aYOgRZN{[Xl?NV\lN2tEOTBizszNNHXPUGUzPC92ODDoMlvMSG1UVw>?M37QU4lv\HWlZYOgZZBweHSxc3nzNFPITpozPDZ6NkC4NC=>
Nalm6 NUDaOZRlTnWwY4Tpc44hSXO|YYm=M2HTWVExNzJyIN88US=>NXz2XmhWOjRiaB?=M3fwRZJme3WudIOgbY4h\GWlcnXhd4VlKFCWRV6gdIhwe3Cqb4L5cIF1cW:wIHH0JJRp\SCFS{KgeIFz\2W2IILld4llfWViU{O4NEBidmRiY3;uZ49ucXSjboSg[I94dnKnZ4XsZZRqd25ib3[gVHRGViCycn;0[YlvKGW6cILld5Nqd25?NVzZWWtyOjR3NkG3PVI>
SUP-B15M{O5cGZ2dmO2aX;uJGF{e2G7NH;rTocyOC9{MDFOwG0>NFO5ZlkzPCCqMmfidoV{fWy2czDpckBl\WO{ZXHz[YQhWFSHTjDwbI9{eGixconsZZRqd25iYYSgeIhmKEONMjD0ZZJo\XRicnXzbYR2\SCVM{iwJIFv\CClb37jc41qfGGwdDDkc5dvemWpdXzheIlwdiCxZjDQWGVPKHC{b4TlbY4h\XiycnXzd4lwdg>?NWL6[IFPOjR3NkG3PVI>
Nalm6 M4joSWFxd3C2b4Ppd{BCe3OjeR?=NFzteo83NzFyIN88US=>M{nXVVQ5KGh?M3THRYlv\HWlZYOgZZBweHSxc3nzMmLyNlQ2PjF5OUK=
SUP-B15NG\mVW1CeG:ydH;zbZMhSXO|YYm=NWHjb|B[Pi9zMDFOwG0>M2CwRVQ5KGh?MXPpcoR2[2W|IHHwc5B1d3Orcx?=NI\WNmszPDV4MUe5Ni=>
C2C12NFzaR5RHfW6ldHnvckBCe3OjeR?=NGTGXmc{KM7:TR?=MXOxNk8zPC92ODDoNV7Mc4g3cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhd3O2ZX;jcIF{fCCmaX\m[ZJmdnSrYYTpc44hdWG{a3Xyd{BidmRiQXv0JJBpd3OyaH;yfYxifGmxbh?=MWGyOFI6OzBzMR?=
JurkatMmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWS4RVAxOS1zMDFOwG0>NVvzcZNWPDhiaB?=M4DVVGlEPTB;ND65JO69VQ>?NHfEUpMzPDJ3M{CyOC=>
CEM-RNFKydZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorCNU0yOCEQvF2=M3\RXlQ5KGh?MULJR|UxRTRizszNNXHTb3hFOjR{NUOwNlQ>
CEM-SMkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3iNU0yOCEQvF2=MYS0PEBpMon6TWM2OD12Lk[g{txOMl70NlQzPTNyMkS=
MOLT-4MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL1fm9rOS1zMDFOwG0>NVzWPHJWPDhiaB?=NGjsXI9KSzVyPUWuO{DPxE1?NXHQfXRnOjR{NUOwNlQ>
PF-382MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLvXHYyNTFyIN88US=>MkHoOFghcA>?MWfJR|UxRTRwNTFOwG0>MnHhNlQzPTNyMkS=
ALL-SILNWjNZYl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWSxMVExKM7:TR?=NYXzd3N7PDhiaB?=MWjJR|UxRTVwNzFOwG0>NGH3SHozPDJ3M{CyOC=>
HPB-ALLNWOwNm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrycpgyNTFyIN88US=>NX:3RVdMPDhiaB?=NX3FW4VOUUN3ME22MlEh|ryPNUPCSlhoOjR{NUOwNlQ>
DND-41MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYSxMVExKM7:TR?=NYnlUFZEPDhiaB?=MXTJR|UxRTlizszNNUn5T4NuOjR{NUOwNlQ>
ALL-SILNVi1bGIySXCxcITvd4l{KEG|c3H5NGX2TFc2KM7:TR?=NFfEdoczPC92ODDoNYHQVWU4cW6mdXPld{BieG:ydH;zbZM>NV;3NW5bOjR{NUOwNlQ>
DND-41MVTBdI9xfG:|aYOgRZN{[Xl?M1LJcFUh|ryPM4TkeFI1NzR6IHi=NILNR5BqdmS3Y3XzJIFxd3C2b4Ppdy=>MVyyOFI2OzB{NB?=
MOLT-4MnryRZBweHSxc3nzJGF{e2G7NUK4UlRiPSEQvF2=M3vlbVI1NzR6IHi=M12yV4lv\HWlZYOgZZBweHSxc3nzM3HWfVI1OjV|MEK0
U-266M2m4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XNO|AuPDBizszNMWW0PEBpMWHJR|UxRTF7LkigxtVOyqB?MUKyOFA5PjR7NB?=
INA-6M1zZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUWwMVQxKM7:TR?=M1K0W|Q5KGh?Ml3oTWM2OD1{LkSyJOK2VQ>?NV3CUGI2OjRyOE[0PVQ>
Jeko-1NFjNfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUSySXl1OC12MDFOwG0>NWjNPWFKPDhiaB?=NHTsXpRKSzVyPUKuOEDDvU4EoB?=MmXzNlQxQDZ2OUS=
Rec-1NV:xWYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYewMVQxKM7:TR?=M1;HelQ5KGh?NYG1XWh3UUN3ME2xMlQ3KML3TdMgM4fNRVI1ODh4NEm0
A549M4P2TGZ2dmO2aX;uJGF{e2G7MYmxNEDPxE1?NH70Z4UyOi9{ND:0PEBpM4nKUYlvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDtbYdz[XSrb36gZY5lKGmwdnHzbY9vNUH2e3l5OjRyMkO5N|g>
A549NEfFWIVHfW6ldHnvckBCe3OjeR?=MWmzJO69VQ>?M{D6UVQ5KGh?NETKNlRqdmirYnn0d{BVT0ZvzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCVbXHkJIFv\CCneIDy[ZN{cW:wIH;mJHNv[WmuIHHu[EBVf2m|dB?=NFLVXpAzPDB{M{mzPC=>
S-LAMA84NGf1ZmlHfW6ldHnvckBCe3OjeR?=M171UFPDqM7:TR?=M4\MeVI1KGh?NHr4TFVFVVORNF73[Glz\WS3Y3XzJGNMOiCjY4Tpeol1gQ>?MUCyOFAyOjFyOR?=
R-LAMA84NY\2SW1iTnWwY4Tpc44hSXO|YYm=M33hcVPDqM7:TR?=M2jwb|I1KGh?MWPEUXNQNEXTWGxz\WS3Y3XzJGNMOiCjY4Tpeol1gQ>?MoS3NlQxOTJzMEm=
S-LAMA84M3fTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PIOlIvPS1zMDFOwG0>M2KycFQ5KGh?MlnKSG1UVw>?NGPD[HBqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6MnfQNlQxOTJzMEm=
R-LAMA84MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HwRlIvPS1zMDFOwG0>NHjOXGE1QCCqNGXTXJNFVVORM1PmSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>MY[yOFAyOjFyOR?=
A549MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWG3d41kOC1|MDFOwG0>NEXsVng4OiCqNVK2d3ZQTE2VTx?=NICyPZdKSzVyPUSuNVUh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5NIjNXFczOzZ3MUS0Ny=>
H1299MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILySYQxNTNyIN88US=>M3u4cVczKGh?NGTEbFBFVVORMYTJR|UxRTFwOECg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDjc45k\W62cnH0bY9vKGSncHXu[IVvfGy7M2PKc|I{PjVzNESz
A549MkjJSpVv[3Srb36gRZN{[Xl?NXv5fmN2OS9zMDFOwG0>M37EUFQ5KGh?M1;ySGROW09?MoTzcIVi\HNidH:gZUBld3OnLXTldIVv\GWwdDDk[YNz\WG|ZTDpckBPd3SlaDDy[ZBwenSncjDhZ5Rqfmm2eR?=MU[yN|Y2OTR2Mx?=
LNCapM2TDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrNbXpSOC1|MDFOwG0>M1PvfVQh\A>?MXvJR|UxRTRwNUpCpO69VQ>?M2nUSVIzQDN{M{G2
A431 NXvoXm94TnWwY4Tpc44hSXO|YYm=NU\rfm9TOTBizszNM1KzO|MxKG2rbh?=MUDheJRmdnWjdHXzJHBKO0tvQXv0MY1VV1Jic3nncoFtcW6pM124b|IzOzh5OUi4
H2170 MX;GeY5kfGmxbjDBd5NigQ>?MXexNEDPxE1?NICySG4{OCCvaX6=MWXheJRmdnWjdHXzJHBKO0tvQXv0MY1VV1Jic3nncoFtcW6pM2PyVVIzOzh5OUi4
A431 MWTGeY5kfGmxbjDBd5NigQ>?M1m5blExKM7:TR?=M4jYN|QuOjRiaB?=MWTlcohidmOnczDhdI9xfG:|aYOge4l1cCCncnzveIlvcWJ?NFLtbI0zOjN6N{m4PC=>
H2170 MlP5SpVv[3Srb36gRZN{[Xl?M37oV|ExKM7:TR?=M37DcVQuOjRiaB?=NXTTcY1M\W6qYX7j[ZMh[XCxcITvd4l{KHerdHig[ZJtd3SrbnniMV6yNlM5Pzl6OB?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of CX-4945 at 25 mg/kg or 75 mg/kg twice daily displays potent antitumor activity in the BT-474 model, with TGI of 88% and 97%, respectively, and 2 of 9 animals in each group showing more than 50% reduction in tumor size compared with the initial tumor volume. In the BxPC-3 model, CX-4945 treatment at 75 mg/kg twice daily shows 93% TGI with 3 animals having no evidence of tumor remaining at the end of the treatment period. [1] In PC3 xenograft model, administration of CX-4945 at 25 mg/kg, 50 mg/kg, or 75 mg/kg causes tumor growth inhibition with TGI of 19%, 40%, and 86%, respectively. [2]
Features First clinical inhibitor of CK2.

Protocol(Only for Reference)

Kinase Assay: [2]

CK2 Kinase Assay CX-4945 is added at a volume of 10 μL to a reaction mixture comprising 10 μL of assay dilution buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM β-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol), 10 μL of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 μL of recombinant human CK2 (ααββ-holoenzyme, 25 ng dissolved in ADB). Reactions are initiated by the addition of 10 μL of ATP solution (90% 75 mM MgCl2, 75 μM ATP (final ATP concentration=15 μM) dissolved in ADB; 10% [γ-33P]ATP (stock 1 mCi/100 μL; 3000 Ci/mM and maintained for 10 minutes at 30 °C. The reactions are quenched with 100 μL of 0.75% phosphoric acid and then transferred to and filtered through a phosphocellulose filter plate. After washing each well five times with 0.75% phosphoric acid, the plate is dried under vacuum for 5 minutes and, following the addition of 15 μL of scintillation fluid to each well, the residual radioactivity is measured using a Wallac luminescence counter. The IC50 values are derived from eight concentrations of CX-4945 over a range of 0.0001 μM to 1 μM.

Cell Assay: [1]

Cell lines SKBr3, MDA-MB-453, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-468, T47D, MCF 7, Hs578T, MDA-MB-361, UACC-812, et al.
Concentrations Dissolved in DMSO, final concentrations ~100 μM
Incubation Time 4 days
Method Cells are seeded at a density of 3,000 cells per well 24 hours prior to treatment, in appropriate media, and then treated with various concentrations of CX-4945. Suspensions cells are seeded and treated on the same day. Following 4 days of incubation, Alamar Blue (20 μL, 10% of volume per well) is added and the cells are further incubated at 37 °C for 4-5 hours. Fluorescence with excitation wavelength at 530-560 nm and emission wavelength at 590 nm is measured.

Animal Study: [1]

Animal Models Female immunocompromised mice CrTac:Ncr-Foxn1nu injected with BxPC-3 or BT-474 cells
Formulation Dissolved in DMSO, and diluted in PBS
Dosages 25 or 75 mg/kg
Administration Oral gavage twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Siddiqui-Jain A, et al. Cancer Res, 2010, 70(24), 10288-10298.

[2] Pierre F, et al. J Med Chem, 2011, 54(2), 635-654.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02128282 Recruiting Cholangiocarcinoma Senhwa Biosciences, Inc. June 2014 Phase 1|Phase 2
NCT01199718 Recruiting Multiple Myeloma Cylene Pharmaceuticals September 2010 Phase 1
NCT00891280 Recruiting Advanced Solid Tumors|Breast Cancer|Inflammatory Breast Cancer|Castlemans Disease|Multiple Myeloma Cylene Pharmaceuticals February 2009 Phase 1

Chemical Information

Download CX-4945 (Silmitasertib) SDF
Molecular Weight (MW) 349.77
Formula

C19H12ClN3O2

CAS No. 1009820-21-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 16 mg/mL (45.74 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Casein Kinase Products

Recently Viewed Items

1  Questions/Answers

Is CX-4945 taken up and effective in yeast cells?

Read More

Currently, no publication reports test of CX-4945 on yeast cells. However, the co-crystal structure of CX-4945 with human CK2 alpha subunit is available. You can check to see if the domains that interact with CX-4945 are conserved between human and yeast. If yes, you may see an effect in yeast cells.

Read More
Tags: buy CX-4945 (Silmitasertib) | CX-4945 (Silmitasertib) supplier | purchase CX-4945 (Silmitasertib) | CX-4945 (Silmitasertib) cost | CX-4945 (Silmitasertib) manufacturer | order CX-4945 (Silmitasertib) | CX-4945 (Silmitasertib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us